First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author García-Alfonso, Pilar
• dc.contributor.author Montagut Viladot, Clara
• dc.contributor.author Aranda, Enrique
• dc.contributor.author Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
• dc.date.accessioned 2022-06-01T06:26:45Z
• dc.date.available 2022-06-01T06:26:45Z
• dc.date.issued 2021
• dc.description.abstract Background: Biologicals, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding the appropriate management of older patients with mCRC is limited. Objective: This study was undertaken to compare the efficacy and safety outcomes in older versus younger patients with mCRC who received first-line biological therapy. Methods: This retrospective analysis used pooled data from five trials undertaken by the Spanish Cooperative Group for the Treatment of Digestive Tumours. All were studies of adults with advanced CRC who received first-line treatment with chemotherapy plus bevacizumab, cetuximab or panitumumab, stratified by age (≥ 65 vs. < 65 years). Endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Results: In total, 999 patients from five studies were included in the analysis: 480 (48%) were aged ≥ 65 years, and 519 (52%) were aged < 65 years. Median PFS did not differ significantly between patients aged ≥ 65 and < 65 years (9.9 vs. 9.4 months; hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.88-1.17). Median OS was significantly shorter in older than in younger patients (21.3 vs. 25.0 months; HR 1.21; 95% CI 1.04-1.41). There was no significant difference between older and younger patients in ORR (59 vs. 62%). Patients aged ≥ 65 years experienced significantly more treatment-related grade 3 or higher adverse events (61.67%) than did patients aged < 65 years (45.86%). Conclusions: Biologicals plus chemotherapy is an effective first-line treatment option for selected patients aged ≥ 65 years with mCRC and has a manageable safety profile and efficacy comparable to that observed in younger patients.
• dc.format.mimetype application/pdf
• dc.identifier.citation García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, et al. First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Drugs Aging. 2021 Mar; 38(3): 219-31. DOI: 10.1007/s40266-021-00834-w
• dc.identifier.doi http://dx.doi.org/10.1007/s40266-021-00834-w
• dc.identifier.issn 1170-229X
• dc.identifier.uri http://hdl.handle.net/10230/53339
• dc.language.iso eng
• dc.publisher SpringerOpen
• dc.rights Copyright © The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.other Quimioteràpia
• dc.subject.other Persones grans
• dc.subject.other Còlon--Càncer
• dc.title First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion